In the event of a pandemic, this needle-free system could be rapidly disseminated to provide protection against a deadly influenza outbreak, such as H5N1 influenza or bird flu. Company’s technology has the potential to improve vaccine effectiveness to protect against a range of agents, including potential bioterror agents, by delivering therapeutics directly through the skin without needles, thus reducing required dosage and extending vaccine supplies.
Kevin Marchitto, CEO of Rocky Mountain, said: “With SAVE technology, we believe we can deliver vaccine protection to nearly all of the US population within days of an outbreak. In addition, the effectiveness of technology may reduce the amount of vaccine required, as well as provide greater immunity to the very young and elderly.”